Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Issue Date:

ARF No: CBE/ARF/000 33

PART A: To be completed by the	Receiv	er (a separate	form must be	completed for e	ach sample	type)	
A1. Details of Sample/Specimen							
Type/ID: (eg primary cell, cell line, tissu fluid, excreta, biological agent)	ie, body	Ficolled primary cord blood units			8	⊠Human □Animal	
Format / Quantity: (eg vials, slides, e	etc)	6x50mL tube containing 20mL ficol unit					
Tissue site/Organ source:		Cord Blood				* *	□N/A
Batch N°:			× ,	а	8	87	
Is the sample/specimen consider If No, go to section A2.	terial under the Human Tissue Act (HTA)?				⊠Yes □No		
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?						use?	⊠Yes □No
Is the material obtained for storage and use under a project specific NHS REC approval?						□Yes□No	
Is the material licensable under the HTA? Indicate source below:							⊠Yes □No
☑HTA licensed organisation ☑C	Commer	cial Supplier	☐ Imported (fro	om outside Engl	and, Wales o	r N.Ireland)	4
If Yes, list lot numbers (or other identifier) & the corresponding productions assigned unique sample ID.		102, 103.	rocessed to 1 x T75 containing 14.5 e6 cells in			Procuro):	
Yes, provide Project Ref N°:			A010, BRA165				
If Yes, provide the name of the PI: Dr Rob Thomas						9 °	
A2. Details of Receipt							
Date/Time of receipt		Date	19/07/2018	Time:			
ID of Receiver		Name:	Jon Harriman		Dept:	СВЕ	
ID of Supplier/Provider		Name:	Anthony Nolan		Country:	UK ,	
PART B: To be completed by the	Receive	er					
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		⊠Yes □No	Ref Number: BRA060, BRA010, BRA165				
Physical integrity of the material(s) acceptable?		⊠Yes □No	If No, describe action taken				
Quantity received correct?		⊠Yes □No	If No, describe action taken				
Labelling correct and legible?		⊠Yes □No	If No, describe action taken				
Is the relevant documentation attached to this form?	C of A	or equivalent	evidence of	⊠Yes □No □N/A			
If No, add reference or details	Agreements to enal			⊠Yes □No □N/A			

to ensure traceability	Details/evidence/assurance of consent		⊠Yes □No □N/A			
	Other (describe	a) :	□Yes □No □N/A			
Temporary storage - Quarantine location (as applicable)	Building/Room		Once processed will be stored in H27 incubator A for 4 days culture then frozen down into 24x 1mL vials and stored in Bank 1. Exact location TBD.			
	Storage Unit ID					
	Within storage	unit location ID	H27 Incubator A			
	Date/Time of q	uarantine	03/09/2018			
Submitted by:	Signature:		Date: 03/09/2018			
PART C: To be completed by the	e departmental Q	uality Manager	建筑设置指示 的			
C1. Quality Assurance Checks						
Has the sample/specimen been	☐Yes □No □N/A ☐N/A					
Has the donor been screened fo	□Yes □No □N/A					
Has the sample/specimen been	☐Yes ☐No ☐N/A					
Is there evidence that the suppli or other recognised certification	☐Yes ☐No ☐N/A					
For HTA licensable material, is the and use of the material under the	☑Yes □No □N/A					
Is there sufficient evidence to su	□Yes ☑No □N/A					
C2. Approval for release from q	uarantine			/		
Can the material be released fro released for processing?	om quarantine and	transferred to desi	gnated storage area or	☑Yes □No		
		☐Accept as is, b	ut with extra controls	A		
If No, provide recommendations for deposition of the material and the results of any action		☐Rework or rep	rocess to meet the ments	* * *		
		☐Test to meet s	pecified requirements			
relating to non-conforming mate	riai.	☐Return to supp	olier/provider			
		□Disposal				
If Yes, provide details of storage applicable)		Building/Room				
		Storage Unit ID		e		
	location (as	Within storage u	nit location ID	Man Incubator		
		Database Refere	nce	* *		
	Date/Time of tr		nsfer			
Approved by:		Signature:	a	Date:		